文献速递白血病造血干细胞移植与细胞治疗

初治异基因造血细胞移植对比缓解诱导化疗后异基因造血细胞移植治疗伴多系发育异常的急性髓系白血病:倾向评分匹配分析

Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis.
PubMed 文献 · Am J Hematol · 2018-11-29

该回顾性研究基于日本登记数据,纳入2007至2016年间接受异基因造血细胞移植的1445例成人伴多系发育异常急性髓系白血病患者,经倾向评分匹配后每组269例。两组总生存无显著差异,初治移植组白血病相关死亡率累积发生率显著低于诱导化疗后移植组。作者认为符合移植条件者应考虑初治移植。

要点

  • 倾向评分匹配后每组269例,两组总生存无显著差异。
  • 初治移植组白血病相关死亡率累积发生率显著低于诱导化疗后移植组。
  • 60至70岁、诊断时白细胞<3000/μL、不良细胞遗传学风险、清髓性预处理及脐血移植亚组中初治移植白血病相关死亡率显著降低。

核心结论

  • 作者认为移植前诱导化疗对伴多系发育异常急性髓系白血病患者移植后生存无任何获益。
  • 初治移植有助于降低移植后白血病相关死亡率累积发生率。
  • 作者建议对符合异基因造血细胞移植条件的伴多系发育异常急性髓系白血病患者考虑初治移植。
  • 两组总生存无显著差异。

研究设计与样本

  • 回顾性分析日本登记数据,纳入2007年至2016年间接受异基因造血细胞移植的1445例成人伴多系发育异常急性髓系白血病患者。
  • 采用倾向评分匹配,匹配后初治移植组269例、诱导化疗后移植组269例。

主要发现

  • 两组总生存无显著差异。
  • 初治移植组白血病相关死亡率累积发生率显著低于诱导化疗后移植组。
  • 亚组分析显示,60至70岁患者中初治移植组白血病相关死亡率发生率显著降低。
  • 诊断时白细胞计数<3000/μL患者中初治移植组白血病相关死亡率发生率显著降低。
  • 不良细胞遗传学风险、接受清髓性预处理及脐血移植患者中初治移植组白血病相关死亡率发生率显著降低。

临床怎么用

  • 作者建议对符合异基因造血细胞移植条件的伴多系发育异常急性髓系白血病患者考虑初治移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The efficacy of induction chemotherapy before allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia with multilineage dysplasia (AML-MLD) is unclear. Some patients with AML-MLD have received upfront HCT without prior induction chemotherapy. To compare the transplant outcomes between patients who received upfront HCT and those who received induction chemotherapy followed by allogeneic HCT for AML-MLD, we retrospectively analyzed the Japanese registration data of 1445 adult patients who had received allogeneic HCT between 2007 and 2016. Propensity score matching identified 269 patients in each cohort. There were no significant differences in overall survival between the two groups. The cumulative incidence of leukemia-related mortality was significantly lower in patients who received upfront HCT than those who received induction chemotherapy before HCT. In the subgroup analyses, upfront HCT had a significantly reduced incidence of leukemia-related mortality among patients aged between 60 and 70 years, those with a lower white blood cell count at diagnosis (<3000/μL), and poor cytogenetic risk, and those who received myeloablative conditioning and cord blood transplantation. Our results suggested that induction chemotherapy before HCT did not have any benefits of survival after HCT for AML-MLD. Upfront HCT contributed to the reduced incidence of leukemia-related mortality after HCT. Upfront HCT should be considered for patients with AML-MLD who are eligible for allogeneic HCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Konuma T, Harada K, Yamasaki S, et al. Upfront allogeneic hematopoietic cell transplantation (HCT) versus remission induction chemotherapy followed by allogeneic HCT for acute myeloid leukemia with multilineage dysplasia: A propensity score matched analysis. Am J Hematol. 2018. PMID: 30370944. doi:10.1002/ajh.25336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。